The Role of Laboratory Measurements on D-dimer Level in the Patients with COVID-19: A Retrospective Study
Keywords:
inflammation, thrombosis, COVID-19Abstract
Introduction: Inflammation may raise the concentration of D-dimer level in COVID-19 patients. There is no consensus on the role of inflammation on the D-dimer level in the literature. We aimed to examine the role of inflammation in D-dimer level in COVID-19 patients.
Methods: The patients who were suspected of COVID-19 disease were referred by one of the medical doctors to a private medical lab between 1 July and 30 November 2020. The patients with COVID-19 infection were diagnosed using a combination of IgG and IgM antibodies. The confirmed laboratory patients were considered cases (n=204) and others as healthy controls (n=440) in this case-control investigation.
Results: In this study, the patients were older compared to the healthy controls; 54.5 vs. 51.5 years; P=0.0251. The patients had a significantly higher concentration of D-dimer (483.5 vs. 318 µg/ml; elevated prevalence: 48.53% vs. 22.95%; P<0.001) and significantly higher median CRP concentration compared to the healthy controls (89.0 vs. 36.63 IU/ml (P<0.001), respectively. The patients and controls had a similar median ferritin concentration. The nominal logistic regression model showed that D-dimer (P=0.00274) was the only variant factor between the COVID-19 patients and healthy controls. The CRP concentration was not shown to determine the D-dimer levels in COVID-19 patients.
Conclusions: This study showed that patients with COVID-19 have elevated levels in CRP and D-dimer. The study did not confirm the role of inflammation in elevating D-dimer in COVID-19 patients. The inflammatory and thrombosis markers are required to be measured in COVID-19 patients with different severities at various follow-up periods in a prospective study.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author(s) retain the copyright and the full publishing right without restriction under the Creative Commons Attribution 4.0 International License (CC BY 4.0) which allows readers to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially, provided the work is properly attributed. (https://creativecommons.org/licenses/by/4.0/).
Author(s) grant the non-exclusive publishing right to the Journal of Karnali Academy of Health Sciences (JKAHS). The publishing rights include the rights to publish, reproduce, distribute, include in indexes or search databases or other media in print or online. The JKAHS may require revisions to the manuscript before acceptance for publication or may choose not to publish it based on the judgement of the editors. Further, JKAHS might retract, withdraw, or publish a correction or other notice after publication, if such publication would be inconsistent with the good publication practices and associated guidelines set forth by the COPE (Committee on Publication Ethics) (https://publicationethics.org/core-practices).
More information about the Creative Commons Attribution 4.0 International License can be found in the webpage of Creative Commons (CC) by following the link provided below: https://creativecommons.org/licenses/by/4.0/